A post hoc analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial, including 620 severely obese patients (BMI ≥ 40 kg/m2 or > 120 kg), found comparable safety and effectiveness of rivaroxaban vs warfarin across various BMI subgroups, with no interaction between BMI subgroups (P = 0.69 and P = 0.31, respectively).3 This evidence concerns the gene F10 and Stroke.